Editorially reviewed · Last updated September 8, 2026 · How we review
Part of YouTube & Expert Fact Checks.
Dr. Jones DC on Retatrutide: Trial Results and Food Chatter Claims
This page fact-checks his claims against the published clinical trial data, press releases, and peer-reviewed research.
Phase 3 Breaking News: TRIUMPH-4 Results
Dr. Jones opens with breaking news from TRIUMPH-4, reporting 28.7% weight loss at 68 weeks and flagging a new side effect called dysesthesia. He also reports an 18% dropout rate.
| Claim | Published Data | Verdict |
|---|---|---|
| 28.7% weight loss at 68 weeks | TRIUMPH-4 Phase 3 results (Eli Lilly press release, December 11, 2025): Retatrutide 12 mg achieved 28.7% mean weight loss at 68 weeks under the efficacy estimand. Placebo-adjusted figure was 26.6%. | Accurate |
| Highest weight loss ever recorded in a controlled obesity trial | The 28.7% result was a major December 2025 finding. A claim covering every controlled obesity trial is broader than this source establishes. REDEFINE-4 was reported in 2026, after this video, and should not be used as evidence available to him. | Historical headline; avoid an absolute ranking |
| New side effect: dysesthesia — abnormal skin sensations — 21% on high dose | TRIUMPH-4 reported dysesthesia in 20.9% of participants on the 12 mg dose (8.8% on 9 mg; 0.7% on placebo). Symptoms include tingling, burning, or hypersensitivity to touch. | Accurate |
| 18% of patients dropped out of the medication | TRIUMPH-4 discontinuation due to adverse events: 18.2% for the 12 mg dose, 12.2% for 9 mg, and 4.0% for placebo. The 18% figure is specific to the highest dose, not the overall trial average. | Approximately accurate |
Dr. Jones gets the headline TRIUMPH-4 numbers right. His characterization of dysesthesia as "abnormal skin sensations" is a fair plain-language description. The 18% dropout figure is accurate for the 12 mg dose specifically, though he does not clarify this is dose-specific.
Three Generations of GLP-1 Medications
Dr. Jones frames the evolution of obesity medications as three generations: semaglutide (single agonist, ~15%), tirzepatide (dual agonist, ~21%), and retatrutide (triple agonist, ~24%).
| Claim | Published Data | Verdict |
|---|---|---|
| Semaglutide (generation 1): about 15% body weight loss | STEP 1 trial (Wilding et al., NEJM 2021): Semaglutide 2.4 mg achieved 14.9% mean weight loss at 68 weeks (efficacy estimand). | Approximately accurate |
| Tirzepatide (generation 2): 21% weight loss | SURMOUNT-1 (Jastreboff et al., NEJM 2022): Tirzepatide 15 mg achieved 22.5% at 72 weeks. Lower doses: 15.0% (5 mg) and 19.5% (10 mg). | Approximately accurate |
| GIP reduces nausea that GLP-1 can cause | While the GIP component in tirzepatide is associated with improved tolerability, the mechanism is debated. Some researchers suggest GIP may buffer GI side effects, but the evidence is not definitive. | Approximately accurate |
| GIP acts on fat cells in mobilization of fat that GLP-1 doesn't do | GIP receptors are expressed on adipocytes and may play a role in fat metabolism. However, the precise mechanism of GIP agonism in obesity treatment is still under investigation. The claim is directionally correct but oversimplified. | Approximately accurate |
The generational framing is a useful simplification. His weight loss numbers are close to published data — he rounds semaglutide from 14.9% to "about 15%" and tirzepatide from 22.5% to "21%," both reasonable approximations.
The Glucagon "Third Engine" Mechanism
Dr. Jones uses a car engine analogy — "one engine to two engines to three engines" — and explains that glucagon activation stimulates lipolysis, increases thermogenesis, and creates a "fasting mimicking state."
| Claim | Published Data | Verdict |
|---|---|---|
| GLP-1 and GIP reduce what goes in; glucagon increases what goes out | This is a reasonable simplification. GLP-1/GIP primarily act on appetite, satiety, and gastric emptying (intake side). Glucagon receptor agonism promotes hepatic fat oxidation, energy expenditure, and lipolysis (output side). | Accurate |
| Glucagon stimulates lipolysis (breakdown of fat from fat cells) | Preclinical glucagon research supports hepatic lipid-metabolism effects. Direct fat-cell effects in treated humans and the contribution to retatrutide’s weight loss are not established by the obesity trial. | Mechanistic claim needs qualification |
| Glucagon increases thermogenesis (burns extra calories) | Glucagon receptor agonism has been shown to increase energy expenditure in preclinical models. The Phase 2 weight-loss endpoint cannot measure how much energy expenditure changed or separate it from reduced intake. | Accurate |
| Glucagon creates a fasting mimicking state — your body thinks it's fasting | Glucagon is naturally released during fasting and promotes the metabolic switch from glucose to fat oxidation. Pharmacological glucagon receptor agonism likely mimics aspects of the fasted metabolic state. The term "fasting mimicking" is his own framing, not a standard clinical term. | Approximately accurate |
| Glucagon receptors are heavily concentrated in the liver, flushing fat out | Correct. Glucagon receptors are highly expressed in the liver. Glucagon receptor agonism promotes hepatic fat oxidation and glycogenolysis. The MASLD substudy data supports the liver-specific fat reduction claim. | Accurate |
Retatrutide targets three receptors, but the “intake versus output” account simplifies interacting pathways. Neither the weight-loss result nor the liver MRI substudy proves a fasting-mimicking state or isolates glucagon’s contribution in people.
Liver Fat Reversal Data
Dr. Jones cites the MASLD (fatty liver) substudy results from the Phase 2 trial.
| Claim | Published Data | Verdict |
|---|---|---|
| Over 80% reduction in liver fat on the 12 mg dose | Sanyal et al. (Nature Medicine, 2024): Mean relative reduction in liver fat was 82.4% for the 12 mg group and 81.4% for the 8 mg group at 24 weeks. | Accurate |
| 86% of patients normalized liver fat to under 5% | Sanyal et al.: 86% of participants on 12 mg achieved normal liver fat (under 5%) at 24 weeks. The 8 mg group achieved 79%. | Accurate |
Both figures match the 24-week liver MRI analysis. The substudy was not head-to-head against another medicine, and reducing MRI liver fat below 5% does not demonstrate reversal of fibrosis or a cure for MASH.
Phase 2 Trial Numbers: Weight Loss Thresholds
Dr. Jones walks through the Phase 2 trial results, citing the headline weight loss figure and breaking down what percentage of participants hit various thresholds.
| Claim | Published Data | Verdict |
|---|---|---|
| Phase 2: 338 adults with obesity, no diabetes, 48 weeks | Jastreboff et al. (NEJM 2023): 338 adults with BMI 30 or higher (or 27+ with comorbidities), without diabetes, treated for 48 weeks. | Accurate |
| 12 mg dose: 24.2% average weight loss | NEJM: The 12 mg group achieved 24.2% mean weight loss at 48 weeks. | Accurate |
| 100% on 12 mg lost at least 5% | NEJM: 100% of participants on both 8 mg and 12 mg doses achieved at least 5% weight loss. | Accurate |
| 93% lost at least 10% | NEJM: 93% in the 12 mg group achieved at least 10% weight loss at 48 weeks under the efficacy estimand. His threshold is correct. | Accurate |
| 60% lost at least 20% | The main paper’s 83% figure refers to at least 15%, not 20%. This review could not verify his 60% threshold claim from the retrieved main-paper table. | Not verified here |
| 26% lost more than 30% | This review could not verify the 30% threshold in the retrieved Phase 2 main-paper table. A Phase 3 result at a different threshold and timepoint cannot validate or refute it. | Unverifiable |
His 24.2% headline and 93% achieving at least 10% are supported. The Phase 2 efficacy-estimand percentages for the 12 mg group at 48 weeks were 100% for at least 5%, 93% for at least 10%, and 83% for at least 15%. The earlier version of this fact-check mislabeled those thresholds and wrongly criticized him. The 20% and 30% claims remain unverified here.
Retatrutide vs Tirzepatide: Speed of Weight Loss
Dr. Jones makes a direct speed comparison between tirzepatide and retatrutide, arguing that retatrutide achieved more weight loss in less time.
| Claim | Published Data | Verdict |
|---|---|---|
| Tirzepatide: 22% weight loss at 72 weeks (SURMOUNT trials) | SURMOUNT-1: Tirzepatide 15 mg achieved 22.5% at 72 weeks. He rounds down from 22.5% to 22%. | Approximately accurate |
| Retatrutide: 24% at 48 weeks — more weight loss in less time | Phase 2 (NEJM 2023): Retatrutide 12 mg achieved 24.2% at 48 weeks. The comparison is directionally correct, but these are cross-trial comparisons with different populations and trial designs. | Approximately accurate |
| Tirzepatide weight loss curve plateaus around 20-22% | SURMOUNT-1 data shows the tirzepatide weight loss curve flattening between 60-72 weeks. This is consistent with his description. | Accurate |
| Retatrutide curve at 48 weeks had not plateaued | Confirmed by Jastreboff et al. (NEJM 2023): The weight loss trajectory showed ongoing decline at 48 weeks with no evidence of attenuation. TRIUMPH-4 later reported 28.7% at 68 weeks in a different population; it was not an extension of Phase 2. | Accurate |
| 28-30% weight loss projected in Phase 3 | TRIUMPH-4 confirmed 28.7% at 68 weeks on 12 mg, falling within his projected range. He made this speculation before Phase 3 data dropped, and it proved accurate. | Accurate |
The trial numbers do not establish faster weight loss for a person switching drugs. Differences in population, treatment duration and protocol remain even when efficacy estimands are compared. TRIUMPH-5 is studying retatrutide directly against tirzepatide.
Food Chatter: The Clinical Observation
Dr. Jones introduces his "food chatter" framework — the idea that retatrutide may provide less appetite suppression than tirzepatide for some patients, despite achieving higher weight loss in clinical trials.
| Claim | Published Data | Verdict |
|---|---|---|
| Tirzepatide hits appetite suppression harder than retatrutide for many patients | No head-to-head trial has compared subjective appetite suppression between retatrutide and tirzepatide. Both medications significantly reduce appetite in clinical trials. This is an anecdotal clinical observation, not evidence-based. | Anecdotal — no published evidence |
| Retatrutide patients feel satisfied after eating but food thoughts don't vanish the same way | No published data specifically compares subjective food preoccupation between retatrutide and tirzepatide. Phase 2 retatrutide data did not include patient-reported appetite scales that would allow this comparison. | Anecdotal — no published evidence |
| Some patients report no appetite suppression on retatrutide | An average trial effect cannot disprove an individual’s report of little appetite suppression. The observation does not establish comparative frequency or verify what product the person used. | Individual account; not disproved by a group average |
This is the most speculative section of the video. Dr. Jones is sharing observations from his practice, which can be valuable, but viewers should understand this is anecdotal — not supported by published comparative data. No head-to-head trial has measured subjective appetite suppression between these medications. The "food chatter" framework is his clinical heuristic, not an established medical concept.
Jones says he leads coaching within a telemedicine practice, and the video promotes discovery calls and paid programs. That commercial context is relevant to his decision framework; it does not itself prove his observations wrong. Retatrutide is investigational and cannot be presented as a routine licensed alternative.
Metabolic Markers
Dr. Jones mentions several metabolic improvements seen with retatrutide beyond weight loss.
| Claim | Published Data | Verdict |
|---|---|---|
| 2% drop in hemoglobin A1C | The 2 percentage point HbA1c reduction comes from the Phase 2 diabetes cohort (Rosenstock et al.), not the obesity cohort. In the obesity trial (Jastreboff et al.), HbA1c dropped only 0.4 points from a baseline of 5.7%. He does not specify which population he is referencing. | Misleading without context |
| Triglycerides dropped 40% | The MASLD substudy reported triglyceride reductions greater than 40% at 48 weeks with 8 and 12 mg. The population and endpoint should be named; a general claim cannot be corrected to 30% without specifying the analysis. | Supported in the MASLD substudy; context needed |
HbA1c and triglyceride results should be tied to the relevant populations. A roughly two-percentage-point HbA1c change comes from diabetes research, while the liver substudy supports triglyceride reductions exceeding 40% at higher doses. Neither should silently become the result for every obesity-trial participant.
Heart Rate and Side Effects
Dr. Jones warns about heart rate elevation and sleep disruption as side effects to watch for.
| Claim | Published Data | Verdict |
|---|---|---|
| Heart rate elevation of 10 to 30 beats per minute | The retrieved transcript explicitly calls 10–30 BPM a real-world report. Phase 2 found a smaller average, with dose-dependent increases peaking at 24 weeks and declining thereafter. A trial mean cannot disprove an individual report. | Anecdotal range, not trial-average incidence |
| Sleep disruption is a concern | Jones explicitly says the frequency is unclear and describes reports in practice. Absence from a list of common trial events does not disprove an individual symptom. | Reported observation; frequency unestablished |
The article previously treated Jones’s real-world range as if he claimed it was the trial average. His transcript distinguishes the two. The reports do not establish incidence or causality, and the Phase 2 average should not be used to dismiss a large individual pulse change.
Peptide Recommendations: AOD-9604 and ATX-0304
Dr. Jones discusses AOD-9604 and a compound transcribed as “ATX or O304” — as fat mobilization supplements for patients on tirzepatide who want retatrutide-like metabolic effects.
| Claim | Published Data | Verdict |
|---|---|---|
| AOD-9604 is a fragment of growth hormone that specifically targets fat metabolism | AOD-9604 is a modified fragment of human growth hormone (hGH 177-191). It showed some lipolytic activity in early preclinical and Phase 2 studies, but it failed to demonstrate significant weight loss in a Phase 2b/3 trial (Metabolic Pharmaceuticals, 2007). It is not FDA-approved for any indication. | Overstated |
| ATX-0304 is an AMPK activator similar to MOTC | O304 is an investigational small molecule, not a peptide. An early 28-day diabetes trial and a 2026 ATX-304 Phase 1b conference abstract do not establish safety or effectiveness as an add-on to tirzepatide. | Early evidence; incorrect peptide classification |
The proposed add-ons have not been validated as a way to reproduce retatrutide’s effects. FDA’s review found insufficient evidence of AOD-9604’s effectiveness for obesity. O304/ATX-304 is a small molecule in early clinical research, and neither source establishes the proposed combination with tirzepatide.
Frequently Asked Questions
Who is Dr. Jones DC?
Dr. Jones DC is a doctor of chiropractic who runs the coaching department for a GLP-1 telemedicine practice. He reports losing over 100 pounds himself and says he has personal experience with retatrutide. He is not a medical doctor (MD) or doctor of osteopathy (DO). His "DC" credential is a Doctor of Chiropractic degree. He positions himself as a metabolic optimization coach rather than a prescribing physician.
What are the retatrutide Phase 3 results from TRIUMPH-4?
In adults with obesity or overweight and knee osteoarthritis, TRIUMPH-4 reported 28.7% mean weight loss at 68 weeks with 12 mg and 26.4% with 9 mg under the efficacy estimand. The 12 mg group had 20.9% dysesthesia and 18.2% adverse-event discontinuation. Those rates describe this dose and population.
How does retatrutide compare to tirzepatide for weight loss?
What is dysesthesia from retatrutide?
Dysesthesia means altered or unpleasant skin sensation. TRIUMPH-4 reported it in 20.9% with 12 mg, 8.8% with 9 mg and 0.7% with placebo. Phase 2 had already reported hyperesthesia and skin sensitivity, and current Wegovy and Zepbound labels report dysesthesia too. Its mechanism is not established.
Does retatrutide suppress appetite less than tirzepatide?
No completed direct study cited here establishes that comparison. Jones describes personal and practice observations, which cannot determine comparative frequency or identify a validated “food chatter” treatment algorithm. An average trial benefit does not mean every individual notices the same effect.
Does retatrutide increase heart rate?
Phase 2 reported dose-dependent increases that peaked at 24 weeks and declined thereafter. Jones’s 10–30 BPM range is explicitly attributed to real-world reports, not the trial average. A large or symptomatic increase should be assessed clinically rather than dismissed because the average trial change was smaller.
Is retatrutide FDA approved?
No. Lilly reported TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 results in 2026 and plans a US biologics license application in the first quarter of 2027. Submission is not approval, and there is no established commercial launch date. Other Phase 3 studies continue.
Sources
-
FDA. AOD-9604 evidence review.
-
JCI Insight. O304 early human and preclinical research.
-
Lilly. 2026 program and filing update.
-
Novo Nordisk/FDA. Wegovy label; FDA. Zepbound label.
-
Jones, Dr. (2025). "Doctor Reveals The MOST POWERFUL GLP-1 Yet — Retatrutide Phase 3 Results (28.7% Weight Loss)." Watch on YouTube
-
Eli Lilly and Company. (2025). "Lilly\u0027s triple agonist retatrutide delivered weight loss of average 28.7% in adults with obesity." Press release
-
Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389, 514-526. DOI: 10.1056/NEJMoa2301972
-
Sanyal, A.J., et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine, 30, 2037-2048. DOI: 10.1038/s41591-024-03018-2
-
Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 327-340. DOI: 10.1056/NEJMoa2206038
-
Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989-1002. DOI: 10.1056/NEJMoa2032183
- What this is
- Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
- Regulatory status
- Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
- Our standard
- Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
- No commercial ties
- We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.
Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.
Sources
- Dr. Jones DC on Retatrutide (YouTube)
YouTube
- TRIUMPH-4 results
Eli Lilly Investor Relations
- Phase 2 trial (NEJM)
New England Journal of Medicine
NEJM
The Lancet
JAMA
FDA
ClinicalTrials.govRelated reading
Retatrutide Results and Review: The Weight Loss Data by Dose
Dose-by-dose trial results, with timepoints, analysis differences and limits on predicting individual weight loss.
Retatrutide vs Mounjaro vs Ozempic
Mounjaro and Ozempic are diabetes brands; Zepbound and Wegovy have weight-management indications. Compare their evidence with investigational retatrutide.
Retatrutide Side Effects & Safety Data (2026)
Separate trial tables for retatrutide GI effects and dysesthesia, with rare-event findings and current safety uncertainties.
How Does Retatrutide Work? Mechanism of Action Explained
How the three receptors work, and where proposed mechanisms go beyond demonstrated human effects.
Retatrutide and Fatty Liver Disease (MASLD/MASH)
Phase 2 MRI liver-fat results and their limits: reduced fat is not proof of MASH cure or fibrosis reversal.
Keep exploring
Explore all fact checks topics →